Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by equities researchers at JMP Securities from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, November 22nd, MarketBeat.com reports.
Several other brokerages have also weighed in on ENTA. Zacks Investment Research lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. BidaskClub lowered Enanta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 14th. Berenberg Bank set a $130.00 target price on Enanta Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, September 18th. ValuEngine upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. downgraded Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $86.00 to $57.00 in a research note on Thursday, September 26th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Enanta Pharmaceuticals has an average rating of “Hold” and a consensus price target of $96.50.
Shares of NASDAQ ENTA traded down $2.73 during mid-day trading on Friday, hitting $63.88. 241,278 shares of the company were exchanged, compared to its average volume of 211,274. The stock has a 50 day simple moving average of $62.43 and a 200-day simple moving average of $72.43. Enanta Pharmaceuticals has a 1-year low of $57.15 and a 1-year high of $106.80. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 28.90 and a beta of 0.90.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Thursday, November 21st. The biotechnology company reported $0.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by ($0.12). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $55.95 million. Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. Enanta Pharmaceuticals’s revenue for the quarter was down 23.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 earnings per share. On average, equities analysts anticipate that Enanta Pharmaceuticals will post -0.77 EPS for the current year.
A number of large investors have recently made changes to their positions in the stock. Nuveen Asset Management LLC bought a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $16,686,000. Man Group plc raised its holdings in shares of Enanta Pharmaceuticals by 181.3% in the 3rd quarter. Man Group plc now owns 295,954 shares of the biotechnology company’s stock worth $17,781,000 after buying an additional 190,743 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Enanta Pharmaceuticals by 11.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,528,541 shares of the biotechnology company’s stock worth $128,978,000 after buying an additional 159,504 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Enanta Pharmaceuticals by 8.1% in the 2nd quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock worth $79,721,000 after buying an additional 70,390 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Enanta Pharmaceuticals by 1,189.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 69,102 shares of the biotechnology company’s stock worth $5,831,000 after buying an additional 63,742 shares in the last quarter. Hedge funds and other institutional investors own 89.60% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Further Reading: Different Options Trading Strategies
Receive News & Ratings for Enanta Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.